Phase II study of combination chemotherapy of Carboplatin, Pemetrexed, Bevacizumab and Erlotinib in patients with advanced non-squamous non-small cell lung cancer harboring EGFR active mutation. - Phase II study of 4-drug combination chemotherapy in patients with non-small cell lung cancer harboring EGFR active mutation.

orth East Japan Study Group (NEJSG)0 个研究点目标入组 16 人开始时间: 2017年10月30日最近更新: 2023年10月17日

试验速览

暂无简介。

•1, Evident pulmonary fibrosis or interstitial lung disease on chest X-ray 2, History of radiotherapy for primary lesion (Eligible if primary lesion is out of radiation field) 3, Presence or past history of hemoptysis (>= 2.5 ml) 4, Predisposing factor of airway bleeding i.e. disorder of coagulation, tumor invasion to major vessels, evident cavitary lesions, and tumor invasion of bronchus mucosa 5, Symptomatic central nervous system metastases 6, Active infectious disease (excluding viral hepatitis) 7, Severe complication (congestive heart failure, chronic renal failure, chronic liver failure, bleeding peptic ulcer, paralysis of intestine, ileus, uncontrollable diabetes mellitus, and so on) 8, Ascites or pleural effusion requiring drainage 9, Active double cancer 10, Elective surgery after enrollment of the study 11, Pregnant or lactating females, females of child-bearing potential, and males desiring partner's pregnancy 12, Severe mental disorder 13, Severe drug hypersensitivity 14, Active hepatic disease 15, Any other condition unsuitable for enrolling the study judged by the attending doctor

发起方

orth East Japan Study Group (NEJSG)